Association of Disease Activity with Serum and Tear IL-2 Levels in Behçet Disease

Türkçüoğlu, Peykan; Arat, Yonca Özkan; Kan, Emrah; Kan, Elif Kilic; Chaudhry, Imtiaz A.; Koca, Süleyman Serdar; Çeliker, Ülkü; İlhan, Nevin

doi:10.3109/09273948.2014.1003661

Cited by 9 publications

(8 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Среди обследованных нами 116 пациентов с ББ существенных отличий в концентрации IL-2 у пациентов с активным увеитом и увеитом в ремиссии не выявлено, что согласуется с результатами T rk o lu Р. и соавт. [16] [11]. Помимо МIP-1α и МСР-1 у всех пациентов с ББ существенно по сравнению с КГ уменьшалась частота выявления в СК IFNγ, IL-2, TNFα, GM-CSF и системная продукция Eotaxin, RANTES, MIP-1α, MIP-1β, обладающих провоспалительными и ангиогенными свойствами.…”

Section: цитокины при болезни бехчета с увеитамиunclassified

Features of systemic cytokine production in Behcet's disease associated with uveitis without ocular lesions

et al. 2021

View full text Add to dashboard Cite

Behcet's disease (BD) is a systemic disease underlyed by chronic vasculitis. Hyperactivity of innate and adaptive immunity plays important role in its pathogenesis. Uveitis occurs in 30-70% of the patients, often recurring and reducing visual function. The objective of our work was to study the features of systemic production of immune mediators in BD patients, depending on presence and activity of uveitis. 116 BD patients were divided into 3 groups: (1) 41 patients with active uveitis (UA), (2) 64 subjects with uveitis remission (UR), (3) 11 uveitis-free BD patients (WU). Control group (CG) comprised 34 conditionally healthy people. Detection rate (%) and contents (pg/ml) were measured for IL-1β IL-2, IL-4, IL-5, IL-6, IL-12p70, IL-13, IL-18, IFNγ, CCL2/MCP-1, CCL3/MIP-1α, CCL4/MIP-1β, CCL5/RANTES, CCL11/Eotaxin, СXCL1/GRO-α, CXCL8/IL-8, CXCL10/IP-10, CXCL12/SDF-1α, GM-CSF, TNFα in blood serum by means of multiplex analysis using MAGPIX analyzer (Luminex Corp., USA), Procarta Plex “Human Th1/Th2&Chemokine Panel 20 plex” kits (Bioscience, Austria). TGF-P1, TGF-P2 levels were assayed by ELISA-test (“Vfector-Best”). All the BD patients showed high detection rates of CXCL1/GRO-α (but not its level) in comparison with CG. Detection rate and levels of IL-6, IL-8 were increased in 1st and 2nd BD groups, compared to CG. In UR, unlike UA and WU groups, IL-4 was detected more often than in CG. WU patients showed increased detection rate of only CXCL1/GRO -α. When compared with UA, WU patients had lower serum concentrations of IFNγ, MCP-1, IP-10, MIP-1a, SDF-1α, TGF-β1; UR patients also showed decreased serum levels of IL-18, Eotaxin, GRO-α, RANTES, TGF-β2. Our results indicate the importance of angiogenic and proinflammatory chemokines and cytokines in pathogenesis of BD uveitis, as well as imbalanced production of various immunomediators. Higher detection rates and levels of IL-6 and IL-8 in UA and UR patients may result from weak persistent intraocular inflammation, even upon relief of clinical symptoms, thus, probably, requiring therapeutic correction.

show abstract

Section: цитокины при болезни бехчета с увеитамиunclassified

Features of systemic cytokine production in Behcet's disease associated with uveitis without ocular lesions

et al. 2021

View full text Add to dashboard Cite

show abstract

“…There are several established cytokines such as TNF- α , interferon-gamma (IFN- γ ), interleukin-1 beta (IL-1 β ), IL-6, IL-10, IL-17, and IL-23 known to be involved [ 45 – 47 ]. Furthermore, several “novel” cytokines are now implicated in the pathogenesis of BD including IL-2, IL-12, IL-21, IL-22, IL-33, and IL-37 [ 45 , 48 – 59 ]; however, these require further studies to support a definitive role. Some of these findings have been replicated in the genome-wide association studies (GWAS) [ 60 – 64 ].…”

Section: Immunopathogenesismentioning

confidence: 99%

Knitting the Threads of Silk through Time: Behçet’s Disease—Past, Present, and Future

Adeeb

Stack

Fraser

2017

International Journal of Rheumatology

View full text Add to dashboard Cite

Behçet's disease (BD) is a chronic relapsing vasculitis that affects vessels of all types and sizes with a broad spectrum of phenotypic heterogeneity and complex immunopathogenesis. Efforts by the scientific community to resolve the unmet needs of BD and gaps in our knowledge have been hampered by considerable challenges that primarily relate to the rare nature of the disease in many parts of the world and its heterogeneity. Controversies remain in many aspects of the disease including the diagnostic criteria, immunopathogenesis and biomarker discovery, geographical variation, and therapeutic considerations. In this review, we highlight recent advances in our scientific understanding of BD, shed new insights into diagnostic and treatment strategies, and discuss residual gaps in our knowledge that will serve as the basis for current and future research.

show abstract

“…Th1 and Th17-related cytokines such as interleukin-1β (IL-1β), IL-12, tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ), IL-6 and IL-17 in patients with BD increased levels have been reported [9][10][11]. The kynurenine pathway (KP) is the main route (~95%) of tryptophan catabolism, resulting in the formation of nicotinamide adenine dinucleotide (NAD + ) and various biologically active intermediates such as kynurenine (KYN), kynurenic acid (KYNA), 3hydroxykynurenine (3HK), 3-hydroxyanthranilic acid (3HAA) and quinolinic acid (QUIN) [12].…”

Section: Introductionmentioning

confidence: 99%

Elevated serum levels of kynurenine pathway metabolites in Behçet's patients

Onmaz¹,

Tezcan²,

Sivrikaya³

et al. 2021

Preprint

View full text Add to dashboard Cite

Behçet's disease (BD) is a inflammatory, multisystemic vasculitis of unknown etiopathogenesis. However, innate and adaptive immune system involvement and immune-mediated networks play a key role in the inflammatory cascade. Studies have shown that both indoleamine 2,3-dioxygenase enzyme, which is induced in inflammatory conditions and catalyzes the first and rate-limiting step in the tryptophan (TRP) metabolism by the kynurenine pathway (KP), and downstream metabolites have immunomodulatory properties. The study was aimed to measure KP metabolites levels in patients with BD and to investigate the relationship between disease activity and clinical findings with these metabolites. The study included 120 patients with BD and 120 healthy volunteers. Serum TRP, kynurenine (KYN), kynurenic acid (KYNA), 3-hydroxyanthranilic acid (3HAA), 3-hydroxykynurenine (3HK), quinolinic acid (QUIN) levels were analyzed with tandem mass spectrometric method. Demographic data, clinical manifestations and disease activity score (BDCAF) were recorded. Serum KYN, KYNA, 3HK, 3HAA, QUIN levels and KYN/TRP ratio were higher (p<0.05) in patients with BD compared to the control group, while TRP levels were lower (p<0.05). KYN/TRP ratio and QUIN levels were significantly higher in the presence of neurobehçet's while serum KYN levels were significantly higher in the presence of arthritis (p<0.05). Also, serum QUIN levels were significantly higher in the presence of thrombosis (p<0.05). BDCAF score positively correlated with KYN/TRP ratio and QUIN levels. Our findings showed that serum KP metabolite levels were elevated in patients with BD and there is a relationship between these metabolites with disease activity, clinical findings and inflammatory burden.

show abstract

Association of Disease Activity with Serum and Tear IL-2 Levels in Behçet Disease

Abstract: There was no significant difference in serum or tear IL-2 levels between Behçet patients and controls; there was no association of disease activity with serum and tear IL-2 levels.

Cited by 9 publications

References 28 publications

Features of systemic cytokine production in Behcet's disease associated with uveitis without ocular lesions

Features of systemic cytokine production in Behcet's disease associated with uveitis without ocular lesions

Knitting the Threads of Silk through Time: Behçet’s Disease—Past, Present, and Future

Elevated serum levels of kynurenine pathway metabolites in Behçet's patients

Contact Info

Product

Resources

About